825-P: Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes

Overview of attention for article published in Diabetes, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#40 of 9,705)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 33 news stories from 33 outlets.

• AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ…

• AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ…

• AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ…

• AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 29 additional news stories.